Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group

A. Panovská, L. Němcová, L. Nekvindová, M. Špaček, M. Šimkovič, T. Papajík, M. Brejcha, D. Lysák, J. Zuchnická, J. Novák, D. Starostka, H. Poul, F. Vrbacký, P. Vodárek, R. Urbanová, K. Plevová, Š. Pospíšilová, S. Mašlejová, Y. Brychtová, E....

. 2020 ; 38 (4) : 509-516. [pub] 20200601

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027771

Grantová podpora
NA Czech CLL Study Group
Czech Leukemia Study Group
ML41010 F. Hoffmann-La Roche
MH CZ-RVO 65269705 Ministerstvo Zdravotnictví Ceské Republiky
LQ1601 Ministry of Education, Youth and Sport, CR project NPUII CEITEC 2020
Q28/LF1 Charles University Prague
Q40/08 Charles University Prague

Until recently, a combination of anti-CD20 antibody plus less intensive chemotherapy was a standard of care in elderly population with previously untreated chronic lymphocytic leukemia (CLL). The aim of this observational study was to retrospectively assess efficacy and safety of obinutuzumab + chlorambucil (G-Clb), rituximab + chlorambucil (R-Clb), and bendamustine + rituximab (BR) given as the frontline therapy within routine practice. The final analyzed dataset included 398 consecutive CLL patients from 10 hematology centers cooperating within the Czech CLL Study Group: 63 treated with G-Clb, 78 with R-Clb, and 257 with BR. There were no significant differences in prognostic and predictive markers among the groups. On the contrary, median age at the start of therapy and cumulative illness rating scale (CIRS) score was significantly higher in R-Clb group. Obinutuzumab plus chlorambucil regimen was preferably offered to elderly patients (compared to BR) with less severe comorbidities and lower CIRS score (compared to R-Clb). A time period when a treatment was indicated had also a strong impact on the choice of the regimen. The overall response rate reached 76% (30% complete remissions, CRs) in G-Clb, 75% (22% CRs) in R-Clb, and 85% (47% CRs) in BR group. Median event-free survival was 49.0 months for G-Clb, 20.3 months for R-Clb, and 37.0 months for BR group. Neutropenia grade ≥ 3 developed in 43% of G-Clb, 31% of R-Clb and in 49% of BR patients, grade ≥ 3 infections were recorded in 17% of G-Clb, 6.4% of R-Clb, and 17% of BR patients. In conclusion, real-world therapeutic activity of G-Clb appears to be at least comparable to prospective clinical trial data. R-Clb yields relatively good results in very old and severely comorbid patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027771
003      
CZ-PrNML
005      
20250114091500.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.2744 $2 doi
035    __
$a (PubMed)32400885
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Panovská, Anna $u Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
245    10
$a Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group / $c A. Panovská, L. Němcová, L. Nekvindová, M. Špaček, M. Šimkovič, T. Papajík, M. Brejcha, D. Lysák, J. Zuchnická, J. Novák, D. Starostka, H. Poul, F. Vrbacký, P. Vodárek, R. Urbanová, K. Plevová, Š. Pospíšilová, S. Mašlejová, Y. Brychtová, E. Koriťáková, L. Smolej, M. Doubek,
520    9_
$a Until recently, a combination of anti-CD20 antibody plus less intensive chemotherapy was a standard of care in elderly population with previously untreated chronic lymphocytic leukemia (CLL). The aim of this observational study was to retrospectively assess efficacy and safety of obinutuzumab + chlorambucil (G-Clb), rituximab + chlorambucil (R-Clb), and bendamustine + rituximab (BR) given as the frontline therapy within routine practice. The final analyzed dataset included 398 consecutive CLL patients from 10 hematology centers cooperating within the Czech CLL Study Group: 63 treated with G-Clb, 78 with R-Clb, and 257 with BR. There were no significant differences in prognostic and predictive markers among the groups. On the contrary, median age at the start of therapy and cumulative illness rating scale (CIRS) score was significantly higher in R-Clb group. Obinutuzumab plus chlorambucil regimen was preferably offered to elderly patients (compared to BR) with less severe comorbidities and lower CIRS score (compared to R-Clb). A time period when a treatment was indicated had also a strong impact on the choice of the regimen. The overall response rate reached 76% (30% complete remissions, CRs) in G-Clb, 75% (22% CRs) in R-Clb, and 85% (47% CRs) in BR group. Median event-free survival was 49.0 months for G-Clb, 20.3 months for R-Clb, and 37.0 months for BR group. Neutropenia grade ≥ 3 developed in 43% of G-Clb, 31% of R-Clb and in 49% of BR patients, grade ≥ 3 infections were recorded in 17% of G-Clb, 6.4% of R-Clb, and 17% of BR patients. In conclusion, real-world therapeutic activity of G-Clb appears to be at least comparable to prospective clinical trial data. R-Clb yields relatively good results in very old and severely comorbid patients.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bendamustin hydrochlorid $x aplikace a dávkování $7 D000069461
650    _2
$a chlorambucil $x aplikace a dávkování $7 D002699
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x patologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a indukce remise $7 D012074
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Němcová, Lucie $u Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Nekvindová, Lucie $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
700    1_
$a Špaček, Martin $u 1st Department of Medicine-Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
700    1_
$a Papajík, Tomáš $u Department of Hematooncology, University Hospital, Olomouc, Czech Republic.
700    1_
$a Brejcha, Martin $u Oncology Center, Nový Jičín, Czech Republic. $7 xx0105595
700    1_
$a Lysák, Daniel $u Department of Hematology and Oncology, University Hospital, Plzeň, Czech Republic.
700    1_
$a Zuchnická, Jana $u Department of Hematology, University Hospital, Ostrava, Czech Republic.
700    1_
$a Novák, Jan $u Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Starostka, David $u Department of Hematology, Havirov Hospital and Polyclinic, Havířov, Czech Republic.
700    1_
$a Poul, Hynek $u Department of Hematology, Hospital Pelhřimov, Pelhřimov, Czech Republic.
700    1_
$a Vrbacký, Filip $u 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
700    1_
$a Vodárek, Pavel $u 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic. $7 xx0262638
700    1_
$a Urbanová, Renata $u Department of Hematooncology, University Hospital, Olomouc, Czech Republic.
700    1_
$a Plevová, Karla $u Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Pospíšilová, Šárka $u Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Mašlejová, Stanislava $u Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Koriťáková, Eva $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic.
700    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine-Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic.
700    1_
$a Doubek, Michael $u Department of Internal Medicine-Hematology and Oncology, University Hospital and Masaryk University, Brno, Czech Republic. Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 38, č. 4 (2020), s. 509-516
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32400885 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20250114091457 $b ABA008
999    __
$a ok $b bmc $g 1608106 $s 1118951
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 38 $c 4 $d 509-516 $e 20200601 $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
GRA    __
$a NA $p Czech CLL Study Group
GRA    __
$p Czech Leukemia Study Group
GRA    __
$a ML41010 $p F. Hoffmann-La Roche
GRA    __
$a MH CZ-RVO 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a LQ1601 $p Ministry of Education, Youth and Sport, CR project NPUII CEITEC 2020
GRA    __
$a Q28/LF1 $p Charles University Prague
GRA    __
$a Q40/08 $p Charles University Prague
LZP    __
$a Pubmed-20210105
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace